**dsDNA (Crithidia l.)**

**FA1001**

**100**

    

 **EN**

|  |  |
| --- | --- |
| **Institute Name** | **Date** |
|  |  |

**PRINCIPLE OF THE ASSAY**

The dsDNA (Crithidia l.) kit is an indirect fluorescent antibody assay (IFA) for the qualitative and semi-quantitative determination of anti-dsDNA IgG antibody in human sera. The reaction occurs in two steps:

1. Step one; If dsDNA antibodies are present, a reaction between dsDNA antibodies and the kinetoplast of the Crithidia l. substrate takes place in the first step.
2. Step two; goat anti-human IgG conjugate labeled with fluorescein isothiocyanate (FITC) is added to the substrate. If the patient’s sera contain anti-dsDNA IgG antibody, a positive apple-green fluorescent antigen-antibody reaction will be observed when the slides are examined with the fluorescence microscope. A positive reaction is recognized as an intense staining reaction in the small kinetoplasts of the *Crithidia l.*  organism.

**REAGENTS**

**Materials Provided:**

Each Test System contains the following components in sufficient quantities to perform the number of tests indicated on the packaging label. **NOTE: Conjugate and controls contain a combination of proclin (0.05% v/v) and Sodium azide (<0.1% w/v) as preservatives.**

|  |  |  |  |
| --- | --- | --- | --- |
|

|  |
| --- |
| **S L D** |

 | 1 | Crithidia l. Substrate Slides: Ten, 10-well Slides with blotter. |
| **CONJ** | 2 | Conjugate: Goat anti-human IgG labeled with FITC. Contains phosphate buffer with BSA and counterstain. Two 3.5ml amber-capped bottles. Ready to use. |
|

|  |  |
| --- | --- |
| **CTRL** | **+** |

 | 3 | Positive Control (Human Serum): Will produce positive apple-green staining of the kinetoplast in the Crithidia l. organisms. One, 0.5mL, red-capped, vial. Ready to use. |
|

|  |  |
| --- | --- |
| **CTRL** | **-** |

 | 4 | Negative Control (Human Serum): Will produce no detectable dsDNA staining. One, 0.5mL, green-capped, vial. Ready to use |
|

|  |  |
| --- | --- |
| **BUF** | **PBS** |

 | 5 | Phosphate-buffered-saline (PBS): pH 7.2 ± 0.2. Empty contents of each buffer packet into one liter of distilled or deionized water. Mix until all salts are thoroughly dissolved. Two packets, sufficient to prepare 2 liters. |
|

|  |
| --- |
| **MNTMED** |

 | 6 | Mounting Media (Buffered Glycerol): One, 3.0 ml white capped, dripper tripper vials |
|  | 7 | Cover Glass. Package of twelve, 24 x 60 mm, Thickness #1**.** |

**NOTES:**

**The following components are not kit lot number dependent and may be used interchangeably with the Sebia IFA products, as long as the product numbers are identical: Mounting media (Product #: FA0009S), Negative control (FA2005-IUNC), Cover glass (Product S8007), and PBS (Product #: 0008S).**

**MATERIALS REQUIRED BUT NOT PROVIDED**

1. dIFine® automated microscope or a properly equipped fluorescence microscope.
2. Pipettor(s) capable of pipetting volumes between 10 and 200 uL.
3. Disposable pipette tips.
4. Small test tubes, dilution plate or similar for preparing sample dilutions.
5. Slide Washer, or a large staining dish with a magnetic stir plate for washing slides between incubation steps.
6. Distilled or deionized water.
7. 1 Liter Graduated Cylinder.
8. Laboratory timer to monitor incubation steps.
9. Disposal basin, disposable gloves, and disinfectant (i.e.: 10% household bleach – 0.5% Sodium Hypochlorite).

**STORAGE CONDITIONS**

|  |  |
| --- | --- |
| storage2-8.bmp | Unopened Kit. |
| Mounting Media, Conjugate, Slides, Positive and Negative controls. |
| Rehydrated PBS (Stable for 30 days). |
| storage2-25.bmp | Phosphate-buffered-saline (PBS) Packets. |

**PRECAUTIONS**

1. For *In vitro* diagnostic use.
2. Follow normal precautions exercised in handling laboratory reagents. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing, gloves, and eye/face protection. Do not breathe vapor. Dispose of waste observing all local, state, and federal laws.
3. The wells of the slide do not contain viable organisms. However, consider the slide **potentially bio-hazardous materials** and handle accordingly.
4. The controls are **potentially bio-hazardous materials**. Source materials from which these products were derived were found negative for HIV-1 antigen, HBsAg and for antibodies against HCV and HIV by approved test methods. However, since no test method can offer complete assurance that infectious agents are absent, these products should be handled at the Bio-safety Level 2 as recommended for any potentially infectious human serum or blood specimen in the Centers for Disease control/National Institutes of Health manual “Biosafety in Microbiological and Biomedical Laboratories”: current edition; and OSHA’s Standard for Bloodborne Pathogens (20).
5. Adherence to the specified time and temperature of incubations is essential for accurate results. **All reagents must be allowed to reach room temperature (20 - 250C) before starting the assay**. Return unused reagents to their original containers immediately and follow storage requirements.
6. Improper washing could cause false positive or false negative results. Be sure to minimize the amount of any residual PBS, by blotting, before adding conjugate. Do not allow the wells to dry out between incubations.
7. Conjugate, and controls contain Sodium azide at a concentration of <0.1% (w/v). Sodium azide has been reported to form lead or copper azides in laboratory plumbing which may cause explosions on hammering. To prevent, rinse sink thoroughly with water after disposing of solution containing Sodium Azide. This preservative may by toxic if ingested.
8. Dilution or adulteration of these reagents may generate erroneous results.
9. Never pipette by mouth. Avoid contact of reagents and patient specimens with skin and mucous membranes.
10. Avoid microbial contamination of reagents. Incorrect results may occur.
11. Cross contamination of reagents and/or samples could cause erroneous results.
12. Reusable glassware must be washed and thoroughly rinsed free of all detergents.
13. Avoid splashing or generation of aerosols.
14. Do not expose reagents to strong light during storage or incubation.
15. Allowing the slide packet to equilibrate to room temperature prior to opening the protective envelope will protect the wells and blotter from condensation.
16. Collect the wash solution in a disposal basin. Treat the waste solution with disinfectant (i.e.:10% household bleach - 0.5% Sodium Hypochlorite). Avoid exposure of reagents to bleach fumes.
17. Do not expose any of the reactive reagents to bleach-containing solutions or to any strong odors from bleach-containing solutions. Trace amounts of bleach (Sodium Hypochlorite) may destroy the biological activity of many of the reactive reagents within this Test System.
18. Do not apply pressure to slide envelope. This may damage the substrate.
19. The components of this Test System are matched for optimum sensitivity and reproducibility. Reagents from other manufacturers should not be interchanged. Follow Package Insert carefully.
20. Unopened/opened components are stable until the expiration date printed on the label, provided the recommended storage conditions are strictly followed. Do not use beyond the expiration date. Do not freeze.
21. Evans Blue Counterstain is a potential carcinogen. If skin contact occurs, flush with water. Dispose of according to local regulations.
22. Do not allow slides to dry during the procedure. Depending upon lab conditions, it may be necessary to place slides in a moist chamber during incubations.

**SPECIMEN COLLECTION**

1. Carry out specimen collection in accordance with CLSI document M29: Protection of Laboratory Workers from Occupationally Acquired Infectious Diseases. No known test method can offer complete assurance that human blood samples will not transmit infection. Therefore, all blood derivatives should be considered potentially infectious.
2. Only freshly drawn and properly refrigerated sera obtained by approved aseptic venipuncture procedures with this assay (34, 35). No anticoagulants or preservatives should be added. Avoid using hemolyzed, lipemic, or bacterially contaminated sera.
3. Store sample at room temperature for no longer than 8 hours. If testing is not performed within 8 hours, sera may be stored between 2 - 8°C, for no longer than 48 hours. If delay in testing is anticipated, store test sera at –20°C or lower. Avoid multiple freeze/thaw cycles which may cause loss of antibody activity and give erroneous results. It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine stability criteria for its laboratory (37).

**ASSAY PROCEDURE**

1. Remove slides and other kit components from refrigerated storage and allow them to warm to room temperature (20 - 25°C). Tear open the protective envelope and remove slides. **Do not apply pressure to flat sides of protective envelope.**
2. Identify each well with the appropriate patient sera and controls. **NOTE: The controls are intended to be used undiluted**. Prepare a 1:10 dilution (e.g.: 10µL of serum + 90µL of PBS Buffer) of each patient serum.

**Semi-Quantitative Options:**

* 1. Users may titrate the Positive control to endpoint to serve as a semi-quantitative (1+ Minimally Reactive) control. In such cases, the control should be diluted two-fold in PBS. An endpoint dilution is established and printed on the Positive control vial (± one dilution). It should be noted that due to variations within the laboratory (equipment, etc.), each laboratory should establish its own expected end-point titer for each lot of Positive control.
	2. When titrating patient specimens, initial 1:10 dilutions should be in PBS and all subsequent dilutions should also be prepared in PBS.
1. With suitable dispenser, dispense 20µL of each control and each diluted patient sera in the appropriate wells.
2. Incubate slides at room temperature (20 - 25°C) for 35 ± 5 minutes.
3. Gently rinse slides with PBS. If washing manually **do not direct a stream of PBS into the test wells.**
4. Wash slides for two, 5-minute intervals, changing PBS between washes.
5. Remove slides from PBS one at a time. Invert slide and key wells to holes in blotters provided. Blot slide by wiping the reverse side with an absorbent wipe. CAUTION: Position the blotter and slide on a hard, flat surface. Blotting on paper towels may destroy the slide matrix. **Do not allow the slides to dry during the test procedure**.
6. Add 20-40 µL of conjugate to each well.
7. Repeat steps 4 through 7.
8. Apply 3-5 drops of mounting media to each slide between wells and apply the cover glass. Alternatively, one may apply a small number of mounting media to each well and apply cover glass. Examine the slides immediately with an appropriate fluorescence microscope.

**NOTE: If delay in examining slides is anticipated, seal coverslip with clear nail polish and store in refrigerator. It is recommended that slides be examined on the same day as testing.**

**QUALITY CONTROL**

1. Every time the assay is run, a Positive control and a Negative control must be included.
2. It is recommended that one read the Positive and Negative controls before evaluating test results. This will assist in establishing the references required to interpret the test sample. If controls do not appear as described, results are invalid.
3. Negative control - characterized by the absence of fluorescent staining of the kinetoplast. Staining of the nucleus only and/or staining of the basal body should be interpreted as a negative test.
4. Positive control - characterized by any apple-green fluorescent staining of the kinetoplast. Staining of the basal body **in conjunction with** the kinetoplast should be considered a positive result.
5. Additional controls may be tested according to guidelines or requirements of local, state, and/or federal regulations or accrediting organizations.

**NOTES:**

1. **The intensity of the observed fluorescence may vary with the microscope and filter system used.**
2. **The kinetoplast is generally located closer to the basal body than the nucleus; however, because of the fluid nature of the endoplasm, the location of the kinetoplast may vary from cell to cell (36).**
3. **Read only single, well-defined organisms in each field. Not all organisms will appear optimal; morphology may vary between organisms because of fixation, their stages of growth, and/or their orientation on the slide as they dried (36).**

**INTERPRETATION OF RESULTS**

1. Titers less than 1:10 are considered negative.
2. Positive Test: Any observed apple-green staining of the small kinetoplast of the *Crithidia l.*  substrate organism, at a 1:10 dilution based on a 1+ to 4+ scale. 1+ is considered a weak reaction, and 4+ a strong reaction.
3. For semi-quantitative results, all sera positive at 1:10 should be titrated to endpoint dilution. This is accomplished by making a 1:10, 1:20, 1:40, etc., serial dilution of all positive patient samples. The endpoint is the highest dilution that produces a positive reaction.
4. Staining of both the small kinetoplast and the adjacent larger *Crithidia l.*  nucleus simultaneously should be interpreted as a positive test.
5. Polar staining at the base of the flagella is not significant.
6. Staining of the nucleus only should not be interpreted as a positive test.

**LIMITATIONS OF THE ASSAY**

1. The dsDNA (Crithidia l.) kit is a diagnostic aid. It is therefore imperative that the dsDNA antibody results be interpreted in light of the patient’s clinical condition by a medical authority.
2. SLE patients undergoing steroid therapy may have negative test results (5, 8, and 9).
3. Some drugs, particularly hydralazine, may induce dsDNA antibody production (5, 6, and 8).

**REFERENCES**

1. Robbins WC, Holman HR, Deicher HRG, *et al*: Proc. Soc. Exp. Biol. Med. 96:575, 1957.
2. Seligman M: Cr. Acad. Sci. (Paris), 245:243, 1957.
3. Ceppelini R, Polli E, Celada F: Proc. Soc. Exp. Biol. Med. 96:572, 1957.
4. Deicher HRG, Holman HR, Kunkel HG: J. Exp. Med. 109:97, 1959.
5. Dubois EL: J. Rheumatol. 2:204, 1975.
6. Epstein WV: J. Rheumatol. 2:215, 1975.
7. Blomgren SE: Seminars Heamtol. 10:345, 1973.
8. Alarcon-Segovia D, Fishbein E: J. Rheumatol. 2:167, 1975.
9. Klajman A, Farkas R, Gold E, Ben-Efraim S: Clin. Immunol. Immunopath. 3:525, 1975.
10. Pincus T, Schur PH, Rose JA: N. Engl. J. Med. 281:701, 1969.
11. Koffler D, Carr RI, Agnello V, *et al* : Science 166:1648, 1969.
12. Gershwin ME, Steinberg AD: Arthritis. Rheum. 17:947, 1974.
13. Casals SP, Friou GJ, Myers LI: Arthritis. Rheum. 7:379, 1964.
14. Arana R, Seligmann M: J. Clin. Invest. 46:1867, 1967.
15. Tan EM, Schur PH, Carr RI, *et al*: J. Clin. Invest. 45:1732, 1966.
16. Stollar D, Levine L, Leher HI, *et al*: Proc. Nat’l. Acad. Sci. USA 48:874, 1962.
17. Bosicevich J, Nasou JP, Kayhoe DE: Proc. Soc. Exp. Biol. Med. 103:636, 1960.
18. Jokinen EJ, Julkunen H: Ann. Rheum.Dis. 24:477, 1965.
19. Matrer R, Helgeland SM, Tonder O: J. Immunol. Methods 5:345, 1974.
20. Bickel YB, Barnett EV, Pearson CM: Clin. Exp. Immunol. 3:641, 1968.
21. Davis JS, IV: Arthritis. Rheum. 14:377, 1971.
22. Johnson GD, Edmonds JP, Holbrow EJ: Lancet 2:883, 1973.
23. Wold RT, Young FE, Tan EM, *et al*: Science 161:806, 1968.
24. Farr Rd: J. Infect. Dis. 103:239, 1958.
25. Koffler D, Schur PH, Kunkel HG: J. Exp. Med. 126:607, 1967.
26. Harbeck RJ, Bardana EJ, Kohler PF, *et al*: J. Clin. Invest. 52:789, 1973.
27. Cohen SA, Hughes GRV, Noel GL, *et al*: Clin. Exp. Immunol. 8:551, 1971.
28. Natali PG, Tan EM: J. Clin. Invest. 51:345, 1972.
29. Aarden LA, deGroot ER, Feltkemp EW: Ann. NY Acad. Sci. 254:505, 1975.
30. Slater NGP, Cameron JS, and Lessof MH: Clin. Exp. Immunol. 25:480, 1976.
31. Stingl G, Meingassner JG, Swelty P, *et al*: Clin. Immunol. Immunopath. 6:131, 1976.
32. Davis P, Christian B, and Russel AS: J. Rheumatol. 4:15, 1977.
33. Tourville DR, and Benn V: Microbiological Proceeding, 1977.
34. Procedures for the collection of diagnostic blood specimens by venipuncture. Second Edition: Approved Standard (1984). Published by National Committee for Clinical Laboratory Standards.
35. Procedures for the Handling and Processing of Blood Specimens. NCCLS Document H18-A, Vol. 10, No. 12, Approved Guideline, 1990.
36. U.S. Department of Labor, Occupational Safety and Health Administration: Occupational Exposure to Bloodborne Pathogens, Final Rule. Fed. Register 56:64175-64182, 1991.
37. Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests; Approved Guidelines – 4th Edition (2010). CLSI Document GP44-A4 (ISBN 1-56238-724-3). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, PA 19087.
38. Admou B, Eddehbi FE, Elmoumou L, Elmojadili S, Salami A, Oujidi M, Brahim I, Hazime R. Anti-double stranded DNA antibodies: A rational diagnostic approach in limited-resource settings. Pract Lab Med. 2022 Jun 3;31:e00285. doi: 10.1016/j.plabm.2022.e00285. PMID: 35711387; PMCID: PMC9192786.
39. Pan N, Amigues I, Lyman S, Duculan R, Aziz F, Crow MK, Kirou KA. A surge in anti-dsDNA titer predicts a severe lupus flare within six months. Lupus. 2014 Mar;23(3):293-8. doi: 10.1177/0961203313515763. Epub 2013 Dec 6. PMID: 24316605.
40. Swaak AJ, Groenwold J, Aarden LA, Statius van Eps LW, Feltkamp EW. Prognostic value of anti-dsDNA in SLE. Ann Rheum Dis. 1982 Aug;41(4):388-95. doi: 10.1136/ard.41.4.388. PMID: 6981385; PMCID: PMC1000956.

**GLOSSARY OF SYMBOLS**

The following symbols **may** have been used in the labelling of this product.

| **Symbol** | **Description** | **Symbol** | **Description** |
| --- | --- | --- | --- |
| Ein Bild, das Diagramm, Grafiken, Silhouette, Design enthält.  Automatisch generierte Beschreibung | Manufacturer | Ein Bild, das Screenshot, Kreis, Symbol, Grafiken enthält.  Automatisch generierte Beschreibung | Keep away from sunlight |
| Ein Bild, das Schrift, Grafiken, Symbol, Logo enthält.  Automatisch generierte Beschreibung | *In vitro* diagnostic medical device | Ein Bild, das Symbol, Schrift, Logo, weiß enthält.  Beschreibung automatisch generiert. | Conformity with Directive 98/79 |
| Ein Bild, das Schrift, Symbol, Grafiken, Screenshot enthält.  Automatisch generierte Beschreibung | Catalogue number | **COVGLS** | Cover Glass |
| Ein Bild, das Reihe, Symbol, Schrift, Diagramm enthält.  Automatisch generierte Beschreibungn | Sufficient for *n* tests |

|  |
| --- |
| **S L D** |

 | Substrate Slide |
| Ein Bild, das Schrift, Grafiken, Symbol, Screenshot enthält.  Automatisch generierte Beschreibung | Batch code | A black and white symbol  Description automatically generated with medium confidence | PBS Buffer |
| Ein Bild, das Entwurf, Clipart, weiß, Diagramm enthält.  Automatisch generierte Beschreibung | Use by | MNTMED | Mounting Media |
| Ein Bild, das Diagramm, Reihe, Design enthält.  Automatisch generierte Beschreibung | Storage Temperature limitations | CONJ | Conjugate |
|  | For Prescription Use Only | A red rectangular sign with text  Description automatically generated | Positive Control |
| Ein Bild, das Symbol, weiß, Diagramm, Clipart enthält.  Automatisch generierte Beschreibung | Consult electronic instructions for use | A green rectangle with letters  Description automatically generated | Negative Control |
| Ecommerce This Way Up Icon | Windows 8 Iconpack | Icons8 | Store in the upright position |

|  |
| --- |
| **Made in the USA** |

 | Made in the USA |

For US Customer Service contact your local distributor.

For US Technical Support contact ZEUS Scientific, call toll free or

e-mail support@zeusscientific.com.

For Non-US Customer Service and Technical Support inquiries, please contact your local distributor.

**©2019 ZEUS Scientific. All Rights Reserved.**

****

**ZEUS Scientific.**

200 Evans Way, Branchburg, New Jersey, 08876, USA

Toll Free (U.S.): 1-800-286-2111, Option 2

International: +1 908-526-3744

Fax: +1 908-526-2058

Website: [www.zeusscientific.com](http://www.zeusscientific.com)

****